LB PHARMACEUTICALS INC (LBRX) Stock Price, Forecast & Analysis
NASDAQ:LBRX • US50180M1080
LBRX Key Statistics, Chart & Performance
The current stock price of LBRX is 24.01 USD. In the past month the price increased by 13.42%.
LBRX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to LBRX.
LBRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LBRX. While LBRX has a great health rating, there are worries on its profitability.
LBRX Financial Highlights
Over the last trailing twelve months LBRX reported a non-GAAP Earnings per Share(EPS) of -2.81. The EPS decreased by -905.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.67% | ||
| ROE | -20.34% | ||
| Debt/Equity | 0 |
LBRX Forecast & Estimates
10 analysts have analysed LBRX and the average price target is 43.35 USD. This implies a price increase of 80.55% is expected in the next year compared to the current price of 24.01.
LBRX Ownership
LBRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.34 | 966.197B | ||
| JNJ | JOHNSON & JOHNSON | 21.32 | 586.592B | ||
| MRK | MERCK & CO. INC. | 22.88 | 296.105B | ||
| PFE | PFIZER INC | 9.21 | 154.083B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.25 | 124.384B | ||
| ZTS | ZOETIS INC | 19.09 | 57.184B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.91 | 26.184B | ||
| VTRS | VIATRIS INC | 5.9 | 17.564B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.25 | 13.013B | ||
| AXSM | AXSOME THERAPEUTICS INC | 200.12 | 8.226B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LBRX
Company Profile
LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company is headquartered in New York City, New York and currently employs 16 full-time employees. The company went IPO on 2025-09-11. The firm is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The firm is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The firm is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
Company Info
LB PHARMACEUTICALS INC
One Pennsylvania Plaza, Suite 1025
New York City NEW YORK US
Employees: 16
Phone: 19174506581
LB PHARMACEUTICALS INC / LBRX FAQ
What does LBRX do?
LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company is headquartered in New York City, New York and currently employs 16 full-time employees. The company went IPO on 2025-09-11. The firm is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The firm is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The firm is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
Can you provide the latest stock price for LB PHARMACEUTICALS INC?
The current stock price of LBRX is 24.01 USD. The price decreased by -0.91% in the last trading session.
Does LBRX stock pay dividends?
LBRX does not pay a dividend.
What is the ChartMill rating of LB PHARMACEUTICALS INC stock?
LBRX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for LBRX stock?
LB PHARMACEUTICALS INC (LBRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.81).
Can you provide the number of employees for LB PHARMACEUTICALS INC?
LB PHARMACEUTICALS INC (LBRX) currently has 16 employees.